2727872-68-4
2727872-68-4
Chemical Structure
SRI-42127
- CAS No.: 2727872-68-4
- Formula:C19H20N6O
- Molecular Weight:348.40
IUPAC Name: 3-(1H-indazol-6-yl)-N-methyl-N-(tetrahydro-2H-pyran-4-yl)imidazo[1,2-b]pyridazin-6-amine
InChIKey: AEHZEVSNZUVPNR-UHFFFAOYSA-N
SMILES: CN(C1CCOCC1)C2=NN3C(C=C2)=NC=C3C4=CC5=C(C=C4)C=NN5
Biological Activity: SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SRI-42127 | 99.69% | SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nuvisertib (Standard) | ≥98% | Nuvisertib (Standard) (TP-3654 (Standard)) is the analytical standard of Nuvisertib (HY-101126). This product is intended for research and analytical applications. Nuvisertib (TP-3654) is an orally active second-generation pan-PIM kinase inhibitor with Ki values of 5 nM, 239 nM, and 42 nM against PIM-1, PIM-2, and PIM-3, respectively. Nuvisertib inhibits JAK-independent inflammatory and survival signaling pathways, reduces the production of proinflammatory cytokines, restores apoptotic sensitivity, inhibits mTORC1, MYC, and TGF-β signaling pathways, and decreases the expression of fibrosis markers. Nuvisertib selectively impairs the transport function of ABCG2, resensitizes multidrug-resistant cancer cells to cytotoxic drugs, and overcomes JAK2 inhibitor resistance. Nuvisertib can be used in research related to myelofibrosis, renal cell carcinoma, multidrug-resistant cancer, advanced solid tumors, urothelial carcinoma, and prostate adenocarcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CHR-6494 TFA | CHR-6494 TFA is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 TFA inhibits histone H3T3 phosphorylation. CHR-6494 TFA induces the apoptosis of cancer cells, including melanoma and breast cancer. CHR-6494 TFA can be used in the research of cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
K00135 | 98.03% | K00135 is a potent and selective inhibitor of PIM kinases. K00135 inhibits survival and clonogenic growth of acute leukemia cells. K00135 inhibits the phosphorylation of PIM downstream targets. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IRAK inhibitor 2 | 99.19% | IRAK inhibitor 2 is an interleukin-1 receptor-associated kinase (IRAK) inhibitor. IRAK inhibitor 2 can be used for the research of inflammatory and immune diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SGI-1776 free base | 99.96% | SGI-1776 free base is an orally active Pim kinase and FLT3 inhibitor with IC50 values of 7 nM, 363 nM, 69 nM, and 44 nM for Pim-1, Pim-2, Pim-3, and FLT3, respectively. SGI-1776 free base downregulates C/EBP-α, PPAR-γ, FAS, Leptin, and RANTES, and decreases STAT-3 phosphorylation. SGI-1776 free base induces Apoptosis, cell cycle arrest, mitochondrial depolarization, and reduces RNA synthesis, protein synthesis, and Mcl-1. SGI-1776 free base inhibits adipogenesis and lipid accumulation. SGI-1776 free base has anticancer activity against leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lck-IN-1 | 99.6% | Lck-IN-1 is a potent lymphocyte protein tyrosine kinase (Lck) inhibitor extracted from patent WO2007013673A1, example 48. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CHR-6494 | 99.28% | CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ETC-168 | ETC-168 is a selective and oral active MNK inhibitor with the IC50 values of 23 and 43 nM against MNK1 and MNK2, respectively. ETC-168 shows antiproliferative efficacy in vivo and in vitro. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SRI-43265 | 98.70% | SRI-43265 (compound 40) is an inhibitor of human antigen R protein (HuR) dimerization, and HuR multimers have been implicated in cancer and inflammatory pathogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TRK-IN-32 | TRK-IN-32 is a potent TRK inhibitor. TRK-IN-32 potently inhibits TRKWT, TRKG595R and TRKG667C with IC50 values of 0.08 nM, 2.14 nM and 0.68 nM, respectively. TRK-IN-32 also demonstrates antiproliferative activity against a panel of Ba/F3 cell lines transformed with wild type, xDFG, solvent-front as well as gatekeeper mutant TRK fusion proteins. TRK-IN-32 induces apoptosis of Ba/F3-TRKAWT and Ba/F3-TRKAG667C cells.TRK-IN-32 can be used for the study of various cancers (such as thyroid cancer, secretory breast carcinoma). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
